Examining the link between environmental pollutants and diabetes or thyroid cancer
Association Between Persistent Organic Pollutants and Type 2 Diabetes /Thyroid Cancer
This study is trying to see if being exposed to certain environmental pollutants increases the risk of developing type 2 diabetes or thyroid cancer in people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 900 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Qianfoshan Hospital Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT05218395 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between persistent organic pollutants (POPs) and the development of type 2 diabetes and thyroid cancer. It involves analyzing serum concentrations of various POPs in patients diagnosed with these conditions, as well as a control group of healthy individuals. The study aims to determine whether exposure to these pollutants contributes to the risk of developing endocrine diseases. Participants will be recruited from the First Affiliated Hospital of Shandong First Medical University.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 75 diagnosed with type 2 diabetes or thyroid cancer at the First Affiliated Hospital of Shandong First Medical University.
Not a fit: Patients outside the specified age range or those without a diagnosis of type 2 diabetes or thyroid cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into environmental risk factors for type 2 diabetes and thyroid cancer, potentially guiding prevention strategies.
How similar studies have performed: Previous studies have indicated a potential link between POP exposure and endocrine diseases, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Group of Type 2 diabetes patients: 1. age 18 \~ 75 years old; 2. type 2 diabetes patients diagnosed in the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) , HBA1C ≥7.0% and \<10.5% ; 3. patients signed informed consent. Group of Thyroid Cancer patients: 1. age 18 \~ 75 years old; 2. thyroid cancer patients diagnosed in the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) ; 3. patients who signed the informed consent form. Control Group: 1. age 18 \~ 75 years old; 2. healthy population recruited from the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) ; 3. living in the monitoring area for more than 6 months within 12 months; 4. normal thyroid function and no history of thyroid cancer were needed in the control group; 5. Fasting Blood Glucose level of 0.7 mmol/l was needed in the Control Group of Type 2 diabetes Mellitus Without History of diabetes; 6. patients with informed consent. Exclusion Criteria: * Group of Type 2 diabetes: (1) pregnant, lactating women, patients with acute cardiac cerebrovascular disease; (2) patients with severe liver and Renal Impairment (related laboratory tests more than 2 times the normal) ; (3) patients with Type 1 diabetes; (4) participants in other clinical trials within 3 months; (5) patients with malignant tumors. (6) has the disease and so on serious anemia, is not suitable to carry on the patient which the blood draws the test. Group of Thyroid Cancer: 1. patients with serious heart, liver and Kidney Diseases (related laboratory tests more than 2 times normal) ; 2. patients with other malignant tumors. Control Group: 1. patients with serious heart, liver or kidney disease; 2. patients with iodine or Thyroid hormone; 3. patients with confirmed malignant tumor; 4. pregnant women or those who have recently taken contraception or estrogen.
Where this trial is running
Jinan, Shandong
- Xiaoling Guan — Jinan, Shandong, China (Recruiting)
Study contacts
- Principal investigator: Xiaoling Guan — Qianfoshan Hospital
- Study coordinator: Xiaoling Guan
- Email: gxlwho@163.com
- Phone: 8613356677195
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.